U.S. Consumer Durables Stock News

FFB Bancorp (FFBB) just wrapped up FY 2025 with fourth quarter revenue of US$19.4 million and basic EPS of US$1.08, setting the tone for how the full year is being assessed. Over recent quarters, revenue has moved from US$26.6 million in Q4 2024 to US$27.3 million in Q1 2025, US$24.2 million in Q2 2025 and US$22.8 million in Q3 2025, while quarterly EPS shifted from US$3.06 to US$2.56, US$1.95 and US$2.07 across the same stretch. Taken together with the latest trailing 12 month totals, these...

United Bankshares (NasdaqGS:UBSI) reported record earnings for 2025, supported by its acquisition of Piedmont Bancorp. The company completed the integration of Piedmont Bancorp, adding to its banking footprint and customer base. United Bankshares also finished a substantial share repurchase program, signaling a focus on returning capital to shareholders. United Bankshares operates as a regional banking group, providing lending, deposit, and related financial services to consumers and...

Paychex (NasdaqGS:PAYX) has appointed J. Michael Hansen, former Cintas CFO, to its Board of Directors as an independent director. The move expands the Paychex board and brings additional financial and leadership experience from a veteran executive in related industries. For investors watching Paychex at a current share price of $106.19, the board expansion arrives after a 26.0% decline over the past year and a 7.0% decline over the past 30 days. Over longer periods, the stock shows a 36.0%...

If you are wondering whether Alexandria Real Estate Equities is attractively priced right now, starting with a clear view of its valuation can help you frame that decision. The share price recently closed at US$57.16, with a 17.6% gain over 30 days, a 16.7% return year to date, but a 40.4% decline over 1 year that sits alongside 57.7% and 58.6% declines over 3 and 5 years. These moves sit against a backdrop of ongoing interest in listed real estate and changing sentiment toward specialized...

CorMedix overview and recent share performance CorMedix (CRMD) has drawn investor attention after a sharp pullback over the past month, with the share price down about 38% and roughly 30% lower over the past 3 months. That recent weakness comes despite a 1 day return of 6.74% and a 14.45% move over the past week. This may prompt some investors to reassess how the current price compares with the company’s fundamentals. See our latest analysis for CorMedix. Looking beyond the recent bounce,...

Peoples Bancorp of North Carolina (PEBK) just closed out FY 2025 with fourth quarter revenue of US$24.6 million and EPS of US$1.25, alongside trailing 12 month revenue of US$89.1 million and EPS of US$3.74 that reflects 21.3% earnings growth over the past year. Over recent periods, the company has seen quarterly revenue move from US$21.1 million in Q4 2024 to US$24.6 million in Q4 2025, while quarterly EPS shifted from US$0.67 to US$1.25. This sets up a story where improving margins and a...

U.S. Gold Corp recently advanced its CK Gold Project in Wyoming toward a Definitive Feasibility Study after securing US$31,000,000 in financing, while benefiting from record-high gold prices that enhance project economics and the perceived value of its Nevada and Idaho exploration assets. An interesting angle is how stronger gold prices can make mine-construction financing more attainable, potentially accelerating timelines for turning U.S.-based mineral resources into producing...

If you are wondering whether BridgeBio Pharma's share price still makes sense after a strong run, this article focuses on what the numbers say about value rather than the excitement around the stock. The stock trades at US$77.81, with returns of 2.0% over the past week, 2.7% over the past month, a slight year to date decline of 0.5%, a 112.2% return over the past year, a very large 3 year gain that is around 7x, and a 35.5% return over 5 years. Recent news around BridgeBio has centered on...

Dynex Capital (DX) has wrapped up FY 2025 with Q4 total revenue of US$202.0 million and basic EPS of US$1.17, alongside trailing twelve month revenue of US$372.1 million and EPS of US$2.49. This sits next to a very large 190.8% earnings jump over the past year and an 11.4% annual earnings decline over five years. The company has seen quarterly revenue move from US$60.3 million in Q4 2024 to US$201.997 million in Q4 2025, while basic EPS shifted from US$0.61 to US$1.17 over the same period...

After a strong run, you might be wondering whether Karooooo is still reasonably priced or starting to look stretched at current levels. The stock last closed at US$50.84, with returns of 8.6% over the past week, 7.3% over the last month, 13.8% year to date, and 19.6% over the past year. This puts recent price action front and center for anyone thinking about value. Over the past three years, Karooooo has delivered a total return of 122.8%, which gives useful context to the shorter term moves...

Clover Health Investments (NasdaqGS:CLOV) is reporting strong customer growth for its Medicare Advantage plans and related technology solutions. The company is seeing an expanding free cash flow margin even as revenue has declined over the past two years. This mix of higher customer counts and improving cash generation, alongside revenue pressure, is a fresh development that investors are assessing. Clover Health focuses on Medicare Advantage insurance and technology driven care tools,...

In recent trading, DXP Enterprises has been caught up in past market volatility tied to shifting U.S. trade tensions and tariff threats, while investors also look ahead to an earnings report that is expected to show lower EPS alongside higher revenue. The stock’s moves highlight how external policy uncertainty can weigh on sentiment even when consensus expectations point to continued sales growth and constructive analyst rankings. We’ll now examine how trade-policy uncertainty and the...

FDA Breakthrough designation puts pemvidutide in focus Altimmune (ALT) has drawn fresh attention after the FDA granted Breakthrough Therapy Designation to its lead candidate pemvidutide for MASH, based on mid stage trial data showing significant disease resolution. See our latest analysis for Altimmune. The FDA Breakthrough Therapy news has arrived during a period of building momentum for Altimmune, with the 7 day share price return of 33.49% and year to date share price return of 61.25%...

Daktronics (NasdaqGS:DAKT) announced that Corporate Secretary and Vice President of Human Resources, Carla S. Gatzke, is leaving the company. Her departure affects leadership oversight of human resources and corporate governance functions. Daktronics focuses on electronic scoreboards, large video displays, and digital signage used in sports venues, transportation, and commercial settings. For you as an investor, a change in senior human resources leadership touches on how the company...

Context for JBS (JBS) after recent share moves JBS (JBS) has drawn fresh attention after a recent pullback of about 0.6% in the latest session, alongside gains of roughly 5.9% over the past week and 6.7% over the past month. See our latest analysis for JBS. At a share price of US$15.53, JBS sits on a 90 day share price return of 17.56% and a year to date share price return of 9.52%, suggesting momentum has been building in recent months as investors reassess its risk and growth profile. If...

SM Energy recently drew attention after Zacks assigned it a Rank #5 (Strong Sell), following a decline in consensus earnings estimates that raised questions about its near-term earnings outlook. At the same time, SM Energy’s shares are trading at a discount to peers, creating an unusual mix of weaker earnings expectations and apparently cheaper valuation. With this context in mind, we’ll explore how weaker earnings estimates may influence SM Energy’s investment narrative for investors. The...

If you are wondering whether Victoria's Secret shares still offer value after a strong run, this breakdown is designed to help you weigh what you are paying against what you are getting. The stock last closed at US$58.57, with returns of 8.8% over 30 days and 56.9% over the past year, which has changed how some investors may be thinking about both upside and risk. Recent attention on Victoria's Secret has focused on how the brand is repositioning itself and adjusting its product and...

Super Group (NYSE:SGHC) declared a special dividend following its full year results, highlighting management’s confidence in the business. The payout comes after the company reported strong performance for the year and record highs in active customers and deposits. The decision adds a shareholder income component on top of Super Group’s existing online sports betting and gaming operations. Super Group, which operates online sports betting and gaming brands, is leaning on a growing base of...

If you are wondering whether Hercules Capital is priced attractively right now, you are not alone. Many investors are asking if the current share price lines up with the underlying value. The stock recently closed at US$18.56, with returns of a 1.9% decline over 7 days, a 0.7% decline over 30 days, a 1.6% decline year to date, a 1.6% decline over 1 year and gains of 81.8% over 3 years and 111.6% over 5 years. This naturally raises questions about what is already baked into the price. Recent...

In recent weeks, SPX Technologies drew attention as analysts clarified that the company’s cooling tower products remain important for data center heat management, following earlier concerns about changing cooling technologies. This reaffirmation came alongside commentary highlighting SPX Technologies’ role in specialized HVAC and detection equipment, reinforcing its relevance across industrial, commercial, and utility infrastructure markets. We’ll now examine how this reaffirmed role in data...

HBT Financial (HBT) has wrapped up FY 2025 with fourth quarter revenue of US$59.0 million and basic EPS of US$0.60, while trailing twelve month revenue came in at US$233.9 million and EPS at US$2.44. Over the last few quarters, the company has seen revenue range from US$55.8 million to US$59.2 million per quarter, with quarterly EPS between US$0.58 and US$0.64, giving investors a consistent earnings profile to judge against prior periods. With trailing net profit margins holding in the low...

Steel Dynamics (STLD) has wrapped up FY 2025 with fourth quarter revenue of US$4.4 billion and basic EPS of US$1.83, as the market weighs those figures against a current share price of US$173.32. The company has seen quarterly revenue move from US$3,872 million in Q4 2024 to US$4,414 million in Q4 2025, while basic EPS over that same period shifted from US$1.36 to US$1.83. This is setting the stage for investors to focus closely on how net income trends and margins color the latest set of...

If you are wondering whether FIGS at US$11.26 is still attractively priced after its recent run, this article walks through what the numbers are saying about its current value. The stock has delivered a 96.9% return over the last year and 33.6% over three years, even though the past week and month saw returns of 2.9% decline and 4.7% decline, with a 1.1% decline year to date. Recent attention on FIGS has centered on its position in medical apparel and how the brand is competing in a crowded...

Why Strive Asset Management (ASST) Is Back on Investors’ Radar Strive Asset Management (ASST) has caught investor attention after recent trading, with the share price closing at US$0.79 and short term returns showing mixed results over the past week and month. For you as an investor, the sharper move over the past 3 months, along with a value score of 2 and reported revenue of US$5.51 million against a net loss of US$223.39 million, raises clear questions about risk, valuation and business...